Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 1996

View Archived Issues

Pharmacia & Upjohn, McGill University claim antiparasitic MAb

Novel diagnostic agents for spongiform encephalopathies reported

New calcimimetic agents from ZymoGenetics

Bayer reveals sugar-modified cytostatic agents

New thrombin inhibitors under study at Merck & Co.

Novo Nordisk claims dopamine D3 receptor ligands for CNS indications

VIP analogs and derivatives claimed for smooth muscle relaxation

Therapeutically active NPY analog reported by academic source

Access in-licenses polymer platinum compounds

InSite Vision completes preliminary clinical trial of ophthalmic drug candidate

Dusa photodynamic therapy advances to phase III

Successful phase III results reported for British Biotech PAF antagonist

British Biotech discontinues development of MMP inhibitor

Another British Biotech compound reaches clinical stage

Medarex bispecific antibody enters phase II in colon cancer patients

MGI Pharma acquires drugs from Ilex Oncology

OsmoCyte approved for marketing in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...